BACKGROUND:
In the United States, blood donor testing for hepatitis B surface antigen (HBsAg) was initiated in the early 1970s. More recently, testing for antibody to hepatitis B core antigen (anti-HBc) and hepatitis B virus (HBV) DNA have been added. The incidence of hepatitis B has been declining. This study reviews the current status of testing and questions the need for continuation of HBsAg testing.
STUDY DESIGN AND METHODS: From July 2011 to
June 2015, a total of 22.4 million donations were serologically tested for HBsAg and anti-HBc and for HBV-DNA by nucleic acid testing (NAT). All reactive results were evaluated and a subset of donations that were either potential NAT yield (seronegative) or serologically positive but nonreactive by HBV NAT in minipools (MPs) of 16 were further evaluated by individual donation (ID)-NAT. Samples with detectable HBV DNA were defined as actively infected and considered potentially infectious. CONCLUSIONS: Point estimates of HBV infection rates among blood donors continue to decline, as do those for incidence and residual risk. Elimination of HBsAg screening would have negligible impact, with a risk less than 1 per 4 million donations. C urrently, in the United States, all blood donations are tested for HBsAg, antibody to hepatitis B core antigen (anti-HBc), and hepatitis B virus (HBV) DNA to reduce or eliminate the risk of transfusion transmission of HBV. As judged by the absence of reported confirmed cases of such transmission, the policy appears to be successful. At the same time, it is reasonable to ask if the use of three separate tests is redundant. More specifically, is the continued used of serologic testing for HBsAg justified? 1 Previously, we have reported HBV testing data from almost 13 million donations and have shown that there do not appear to be any donations that are truly positive for HBsAg that would not be detected by routine anti-HBc and HBV DNA nucleic acid testing (NAT), even in minipools (MPs). 1 We have continued the study and now present data on an additional 22.4 million donations, collected over the 4 years ending in June 2015, including an approximately 2-year period when a test system of increased sensitivity for HBV DNA was used. This has allowed for further examination of HBV infection trends in the donor population and an update in estimates of incidence and residual risk. These data are discussed in the context of the feasibility of eliminating HBsAg testing.
RESULTS:

MATERIALS AND METHODS
Blood donors
This study was based on the population of American Red Cross blood donors over the period July 1, 2011 were nonreactive for HBV DNA by MP-NAT were tested by neutralization. In addition, samples that were serology reactive and NAT nonreactive were tested by more sensitive polymerase chain reaction (PCR) methods: UltraQual 1000 (NGI) for HBsAg-reactive samples and for those that were reactive for anti-HBc alone, triplicate testing by PCR (cobas Ampliscreen multiprep, Roche Molecular Diagnostics). The sensitivity of these additional NAT procedures has been estimated at 1 to 2 IU/mL or 4 to 10 copies/mL. 1 Viral loads are expressed as copies/mL with the SuperQuant assay (NGI) having a lower limit of quantitation of 100 copies/mL; a factor of 4 to 5 copies/IU was used for all conversions of IU/mL to copies/mL. Donations positive by UltraQual 1000 but negative by SuperQuant were assigned a viral load of 50 copies/mL. 1 In some cases, in which all test results were not available or could not be fully interpreted, donors were recalled for additional testing. Additional testing on index and/or follow-up samples was performed, as required to arrive at definitive conclusions about the overall status of subjects with respect to HBV infection at the time of the index donation. In addition to repeating standard tests as noted, evaluation included replicate testing (usually 10-fold) with the Procleix discriminatory HBV (dHBV) reagents, and antiHBs testing as needed. 1 
Marker frequency and HBV incidence
The proportion of repeatedly reactive and confirmedpositive markers was reported as events per hundredthousand (pht) donations. Incidence was estimated by the HBsAg-yield method, using the concept that incidence is a function of frequency of samples positive only for HBsAg and DNA, as detected by MP-NAT, divided by the mean duration of that status (44 days), as previously reported. 3 Residual risk, defined as the proportion of donations that were in the window period before the time at which routine screening could identify HBV DNA was calculated based on the incidence and the 18.5-to 26.5-day window period for Ultrio Plus, using MPs of 16, as reported previously. 1 This study reports detailed data from donors defined as actively infected, as indicated by the confirmed presence of detectable HBV DNA in the presence or absence of HBsAg and/or anti-HBc.
Statistical analysis
Comparison of frequencies was performed by chi-square determination or Fisher's exact test, as appropriate. Significance was defined as a p value less than or equal to 0.05.
RESULTS
Primary testing
During the period July 1, 2011, to June 30, 2015, a total of 22,370,271 donations were tested as described. Overall, 49,567 (or 221.6 pht) were repeatedly reactive for anti-HBc and 2987 (13.4 pht) were repeatedly reactive for HBsAg; 1632 were reactive for both markers. MP-NAT identified 1472 donors (6.6 pht), including 48 potential DNA-yield samples of which 29 confirmed (i.e., confirmed HBV DNA in the absence of other HBV markers). Viral loads for the DNA-yield samples ranged from 50 to 70,000 copies/mL (median, 200 copies/mL). Additional testing was performed on the six putatively DNA-positive, HBsAg-positive samples, as outlined in Table 1 . Overall, each of the six donors had HBsAg results with very low S/CO values (S/COs of 4.10 or less). It should be noted that such low values may lead to false-positive interpretations in neutralization testing due to inherent variability of low absorbance values that lead to artificial reductions when comparing the nonneutralized to the neutralized absorbance values. None of the donors had levels of HBV DNA that could be detected by MP-NAT. Further, repetitive NAT with dHBV reagents resulted in minimal signals in three cases with zero of 10 replicates positive in one of two runs. Only one of the six samples (041FQ) had results clearly indicative of the presence of DNA, which happened to be the oldest donor of the group (or of those found in the prior study 1 ) , that is, 56 years old versus 19 to 30 years for the others in both studies. One of the six donor samples (011LS) had anti-HBs at a significant level.
Data trends, incidence, and residual risk
When the current data were compared with data from 2009 through 2011 (Table 2) , with one exception, the rates of each marker did not differ significantly between the two periods, the exception being HBV DNA yield, which was 1 per 2.6 million donations in the earlier period, but 1 in 770,000 donations in the current study (χ 2 = 6.881, p < 0.01). The incidence of new infections, calculated as previously reported, was 1.30 pht person-years in the current study, compared to 1.62 pht person-years in the earlier period; the difference is not significant (χ 2 = 0.73, p = 0.39).
The estimated residual risks using window periods of 26.5 or 18.5 days 1 were, respectively, 1 in 1,060,000 or 1 in 1,520,000.
DISCUSSION
This study extends two prior studies characterizing blood donors actively infected with HBV, almost tripling the amount of data and extending the observation period from 2009 through 2011 to 2015. The data from the prior studies showed a decline in frequency of markers and of the incidence (and thus the residual risk) of HBV infection among US blood donors. 1 The data reported here generally show a continuation of the downward trends that were previously reported. The one exception is significant increase in the frequency of HBV DNA yield samples. This may, in part, be due to the increased sensitivity of the Ultrio Plus test that was introduced about halfway through the study period, but Note that there were six samples that were HBsAg positive without anti-HBc reactivity, but ID-NAT reactive. Further evaluation of these six samples is shown in there is also considerable variability in this measure. This increase in DNA yield was not reflected in measures of incidence, which continued to decline from the previous value of 1.62 to 1.30 pht person-years. Residual risk declined proportionally to 1 in 1,520,000 using an 18.5-day window period. Using the same window period and classical incidence calculations of following seroconverting donors within a 2-year period, Crowder and colleagues 4 reported residual risks in donations from Red Cross donors from 2014 to 2015 of 1 in 1,565,852, or nearly identical to those reported here using HBsAg yield to determine incidence. This increase in detection of HBV DNA was not seen among OBI-positive samples detected only by MP-NAT when comparing the two study periods. Rates of OBI among anti-HBc reactive donations was 0.82% (404/49,567) during this extended period versus 0.91% during the initial period reported in the prior study (273/29,909). 1 However, in this study, of the 404 samples representing OBI, only 43 (10.6%) were detected by MP-NAT; the remaining 361 (89%) required ID-NAT for detection, again like the prior period. This suggests that the vast majority of donors with OBI have DNA levels less than 5 to 10 copies/mL. It is unclear whether such levels would be infectious 5 and the samples were, in any event, detected as a result of anti-HBc reactivity. More recent data from Japan do, however, suggest that even low levels of DNA in donors with OBI may be infectious, on the basis of HBV transmission attributed to components that were nonreactive on tests with a 50% limit of detection of 3.8 to 13 DNA copies/mL. 6 This implies that anti-HBc testing should continue, at least until pathogen inactivation technology is uniformly implemented. In this study, 144 samples had detectable HBsAg without any evidence of other markers, including HBV DNA as detected by ID-NAT. Of these, 47 were from donors who acknowledged a history of HBV vaccination shortly before their donation. All but one of the remaining samples had low HBsAg S/CO levels; all were considered to be falsely positive based on negative HBV DNA results by ID-NAT. Those with low S/CO ratios that were tested did appear to be neutralized, but results of that test are not reliable when S/CO levels are low. It seems likely that these samples were all falsely positive or may have been contaminated with low levels of HBsAg. However, six samples had HBsAg and some evidence of HBV DNA by ID-NAT. These samples were investigated in detail, as indicated in Table 1 . All of them had very low signal levels for HBsAg but the four that were evaluated for neutralization did generate a positive confirmatory result. All of them had at least one positive value on testing by the Ultrio HBV discriminatory test. In two cases, this represented the single test that was performed, but in the other four, 10 replicate tests were performed on two separate occasions. In two cases, only one replicate was positive, in the other two, four of 20 and 15 of 20 were detected. One sample had more than 400 IU/L anti-HBs. It is reasonable to suggest that at least some of these six samples might reflect false positivity or trivial contamination of the test sample with HBsAg or HBV DNA. At face value, however, these six donors would be interpreted as HBsAg confirmed positive with circulating HBV DNA at a level below that which could be detected by routine MP-NAT. These are like the two donations reported in the prior study; in each case, there was reasonable evidence to suggest that those samples were, in fact, false positive. Of the total eight in both studies, only one donor appears to be an outlier (041FQ; Table 1) where he was older than the other seven and his HBV DNA initial and retest replicate testing revealed most replicates as reactive, although no viral load could be generated, thus fewer than 100 copies/mL. Even if all eight donors are assumed to be HBV infected, the overall frequency of this type of sample from the current and previous study is eight in 35 million donations, or one in 4.4 million donations. It is certainly unclear whether such donations would be infectious, with such a low level of HBV DNA.
As a result of this study, we have shown that the finding of donations with apparently detectable HBsAg and a low level of HBV DNA, undetectable by routine testing, is extremely rare at a rate of less than one per 4 million donations. Given that at least some of these samples could reflect sample contamination or a false-positive result, we do not believe that they should preclude serious consideration of elimination of the requirement to test donor blood for HBsAg, provided that sensitive NAT is in place and antiHBc testing continues. The level of risk is less than that which has been accepted as tolerable for other agents, as briefly discussed in a recent publication. 7 However, the continued use of HBsAg testing in confirmatory algorithms will remain important, particularly in the context of donor notification and counseling. Overall, this study demonstrates a continuation of the trends noted earlier in this series and in other studies. 1, 4 The point estimates of the frequency of both chronic and recent infection continue to decline in the American Red Cross donor population. This is consistent with an ongoing decline in hepatitis B in the US population, likely due in large part to the HBV vaccination program. 8 Additionally,
there are ongoing changes in the demographic makeup of the blood donor population as a result of a decline in the demand for blood for transfusion. 
